Author: Eunoia Consulting Co. | Published: September 2, 2026
A practical 12-question framework for veterinary practices evaluating AI tools—covering validation, data use, clinician oversight, integration, change control, incident response, and exit terms.
Veterinary practices are being offered AI tools for documentation, imaging, client communication, scheduling, estimates, reminders, revenue-cycle work, and clinical support. The commercial message is often simple: save time, reduce workload, and improve consistency. The operational decision is not simple.
Every AI product creates a set of questions about clinical responsibility, data use, workflow fit, output quality, vendor change control, and staff readiness. A thoughtful due-diligence process does not mean a practice must delay every tool. It means the practice can distinguish a useful low-risk automation from a product that needs stronger validation, clearer safeguards, or a different deployment model.
The American Veterinary Medical Association has noted that the pace of AI development is outstripping the availability of clear professional guidance. Its discussion of responsible AI highlights the need for explainability, editable outputs, meaningful human oversight, AI literacy, and attention to data privacy. [1] That makes a practical vendor-review process especially valuable for practice owners and leadership teams.
Before asking a vendor about technology, define the work the practice wants to improve. Is the goal to reduce documentation time, improve call handling, identify recall opportunities, support imaging review, or make estimates and follow-up more consistent? Who performs the work today, where does it break down, and how will the practice know the tool improved it?
A vendor demonstration can make a product look broadly capable. A workflow definition keeps the evaluation anchored to a real operating problem. It also establishes the human decision-maker, escalation route, and measures that matter after launch.
Ask for a plain-language description of the input, output, intended user, and permitted action. “AI assistant” is not a sufficiently specific answer. A note-drafting tool, a radiology support tool, and a client-message generator require different controls.
Good due diligence records limitations as clearly as benefits. Ask which species, settings, data conditions, clinical contexts, or workflow situations are outside the intended scope. If the vendor cannot explain boundaries, the practice cannot train staff to use the tool appropriately.
Request validation evidence relevant to the actual practice environment. For clinical tools, ask about the species, case mix, imaging equipment, users, and performance measures used in evaluation. For operational tools, ask about the workflow, integration, accuracy, exception rate, and human-review process.
Do not rely only on a single aggregate accuracy claim. Ask what the measure means, how uncertainty is handled, and how performance is monitored after deployment. The AVMA’s reporting on veterinary imaging AI notes calls for explainable and editable outputs, as well as performance metrics. [1]
“Human in the loop” is only meaningful when the person has enough context, time, training, and authority to challenge the output. Define whether the veterinarian, technician, CSR, manager, or another role reviews the result; what the review requires; and what happens when the user disagrees.
For clinical use, the tool should support professional judgement rather than obscure it. For operational use, staff should be able to override, correct, and flag poor outputs without creating extra invisible work.
Document the data categories, sources, frequency, and minimum necessary fields. Ask whether the vendor receives medical records, imaging, client communications, appointment data, payment data, or audio recordings. Then ask whether the vendor can segregate data by practice, role, or location.
This question should cover hosting, encryption, access, retention, deletion, subprocessors, breach notification, and data ownership. Most importantly, ask whether data is used to train, improve, or evaluate the vendor’s models; whether that is optional; and what contractual terms govern it.
The AVMA has specifically identified privacy concerns around tools that record and transcribe examination-room conversations, including the risk of data being used beyond the care context. [1] Practices should know where a recording goes and what happens to it before activating it.
Ask whether the integration is read-only, write-back, export-based, or API-based. Clarify the fields touched, the failure behaviour, the audit trail, and the rollback path. A convenient integration can create risk if it silently writes incomplete or incorrect information into the practice management system.
AI products change. Models, prompts, knowledge sources, thresholds, interfaces, and integrations can all evolve. Require advance notice for material changes, a description of expected impact, a testing option, a change log, and a route to pause or roll back an update where appropriate.
Ask the vendor to describe incident response, service support, escalation times, evidence preservation, and communication. Your internal plan should also define the manual fallback process. A practice should not discover its fallback only during an outage or a questionable clinical output.
Training should cover not only clicking through features but also appropriate use, limitations, verification, privacy, escalation, and documentation. The AVMA discussion cautions against over-reliance and emphasises the importance of an informed, confident human reviewer. [1]
Agree on a small set of measures before implementation. These could include documentation turnaround, error corrections, client-response time, staff rework, adoption, override frequency, workflow exceptions, or user confidence. Avoid measuring only usage; a widely used tool can still introduce avoidable risk or workload.
Ask about data export, deletion certification, transition support, contract termination, and whether the practice can continue operating if the vendor relationship ends. Exit planning is a governance control, not pessimism.
Not every product needs the same review intensity. A low-risk internal writing assistant may require an approved-use policy and data controls. A tool influencing imaging interpretation, clinical decision support, or treatment communication warrants deeper evidence review, clinician ownership, monitoring, and documented escalation.
The key is to match the governance effort to the potential consequence of a wrong output. A transparent, tiered process is easier for staff and vendors to understand than ad hoc approvals.
Store completed reviews in a central AI inventory. For each tool, retain the use case, owner, risk tier, validation evidence, approved data, contract notes, user guidance, training status, performance measures, change history, and incident record. This avoids repeating the same due diligence for every new conversation and gives leadership a clear view of the practice’s AI footprint.
Eunoia Consulting Co. helps veterinary groups establish repeatable AI vendor-risk assessment and governance processes. Explore our Veterinary AI Vendor Risk Assessment services to evaluate tools with the rigour your practice and clients deserve.
This article was produced by the Eunoia Consulting Co. Editorial Team. Eunoia Consulting Co. specialises in AI governance, healthcare operations, and data strategy for healthcare and veterinary organisations.
[1] AVMA, Building a framework for responsible AI in veterinary medicine